References
- Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. J Am Med Assoc 1996;275:1571–6
- Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289: 2560–72
- European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21: 1011–53
- World Health Organization/International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21: 1983–92
- Erdine S. How well is hypertension controlled in Europe? European Society of Hypertension scientific newsletter: update on hypertension management 2000;1: No. 3. Available at: http://www.eshonline.org/esh/education/newsletter.htm [accessed 16 February 2005]
- Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–7
- Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345–53
- Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003;21(Suppl 2):S43–S46
- Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today 2003;39: 745–61
- Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283–91
- Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003;23: 419–30
- Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19(Suppl 1):S49–S56
- Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(Suppl 2):S24–S28
- Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19(Suppl 1): S41–S48
- Neutel JM, Elliott WJ, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (Greenwich) 2002;4:325–31
- Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083–92
- Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87:37C–43C
- Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004:26(Suppl A):A28–32